Alteplase for treating acute ischaemic stroke
KEYWORDS: alteplase, stroke, manufacturer, treatment, committee, patients, hour, acute, ischaemic, window, hours, model, ischaemic stroke, acute ischaemic, death

The Committee recognised that patients outside the licensed indication for alteplase (under 18 years and over 80 years of age) in England and Wales may have the potential to benefit from treatment with the technology. However, consistent with NICE methods, the Committee was aware that it can only make recommendations based on the current marketing authorisation for alteplase. 4.5 The Committee considered the evidence submitted by the manufacturer on the clinical effectiveness of alteplase. The Committee noted that no clinical- effectiveness data for the 0- to 3-hour treatment window additional to those included in NICE technology appraisal guidance 122 were available, and that clinical-effectiveness data for the 3- to 4.5-hour treatment window were derived primarily from the ECASS 3 trial. The Committee heard from clinical specialists that, although the trial included only a small proportion of patients from the UK, the results of the trial were generalisable to patients receiving alteplase treatment in England and Wales. The Committee also heard from the clinical specialists that it was reasonable for the manufacturer to measure the effectiveness of alteplase from analyses that adjusted for baseline differences in potential confounding variables between the 2 treatment groups. In addition, the clinical specialists noted that
